Trial Profile
Efficacy of low dose Valganciclovir in patients with kidney transplant for cytomegalovirus prevention
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 May 2017
Price :
$35
*
At a glance
- Drugs Valganciclovir (Primary)
- Indications Cytomegalovirus infections
- Focus Therapeutic Use
- 03 May 2017 Results presented at the 2017 American Transplant Congress
- 02 May 2017 New trial record